CRSP - CRISPR Therapeutics GAAP EPS of $1.10 beats by $1.33
2024-02-21 07:44:28 ET
More on CRISPR Therapeutics
- Crispr Therapeutics: Investors Bet Against Casgevy Uptake
- Biotech And Pharma Diversification Pays Off
- Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
- Is Crispr Therapeutics’ high short interest justifiable?
- Crispr, Intellia, and Recursion gain as Ark ETFs boost stakes